Eli Lilly and Company (SWX:LLY)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 573.10B |
| Revenue (ttm) | 43.32B |
| Net Income (ttm) | 9.82B |
| Shares Out | n/a |
| EPS (ttm) | 10.86 |
| PE Ratio | 58.37 |
| Forward PE | 31.55 |
| Dividend | 4.89 (0.78%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | n/a |
| Average Volume | n/a |
| Open | n/a |
| Previous Close | 630.00 |
| Day's Range | n/a |
| 52-Week Range | 540.00 - 833.88 |
| Beta | 0.33 |
| RSI | 50.39 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Novo Nordisk rolls out weight loss drug Wegovy in India, following Eli Lilly’s Mounjaro launch
Eli Lilly: It Is A Bet On Human Longevity
Pharma companies need to beef up M&A right now, says Mizuho's Jared Holz
Jared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Eli Lilly declares $1.50 dividend
Lilly declares third-quarter 2025 dividend
INDIANAPOLIS , June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025 of $1.50 per share on outstanding common ...
Eli Lilly drug bimagrumab saves muscle mass when added to Novo's Wegovy
Eli Lilly's Investigational Oral Pill Shows Weight Loss Benefits With Lingering Side Effect Concerns
Eli Lilly And Co (NYSE: LLY) on Saturday announced detailed results from the ACHIEVE-1 Phase 3 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control...
NHS begins mass rollout of weight-loss jabs to patients in England
About 220,000 patients expected to receive Mounjaro over three years as GPs can prescribe the drugs for the first time Thousands of patients in England will be able to access weight-loss jabs via thei...
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora f...
Notable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focus
Key deals this week: Couchbase, Eli Lilly, NTT Data, QXO, US Steel and more
Eli Lilly posts detailed late-stage trial data for oral weight loss drug orforglipron
Lilly expects orforglipron obesity results in third quarter
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and the company aims to announce in the third quarter trial results for the drug...
Eli Lillys Obesity Pill Appears to Work as Well as Injected GLP-1s
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
The investigational once-daily pill lowered A1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as four weeks, in adults with type 2 diabetes In ACHIEVE-1, orforglipron a...
Final Trade: LLY, SHEL, USO, WMT
The final trades of the day with the Fast Money traders.
Final Trade: LLY, SHEL, USO, WMT
The final trades of the day with the Fast Money traders.
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD ...
Obesity Drugs Help With Weight Loss But Are Adding Fat Elsewhere
A surge in demand for weight-loss and diabetes medications, paired with fears of incoming tariffs, has propelled Ireland to the center of a pharmaceutical trade boom with the U.S., dramatically wideni...
3 'Underdog Stocks' For The Rest Of 2025
With the S&P 500 Index meandering along at a 1.69% year-to-date return, you can't fault investors looking for some juice out of their portfolios at the mid-point of 2025.
Mixed signals in tech and healthcare shake up today's market
Sector Overview: Technology and Healthcare Diverge The US stock market today is a vivid tapestry of mixed signals, with divergence in performance across sectors. The technology sector presents a varie...
Looking At Eli Lilly's Recent Unusual Options Activity
Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly (NYSE: LLY) revealed 13 unusual trades. Delving into the details, we found 23% of tra...
This AI Trader Bought Meta Stock and Dumped Eli Lilly
Traders now can have an AI stockpicker make those tough investment decisions
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand
Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.